Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
复制标题
作者：
血清C-反应蛋白（CRP）水平升高是全身炎症的最确定的标志物之一，可能影响肿瘤免疫微环境状态。因此，我们使用我们的真实世界临床数据集（包括非透明细胞RCC（nccRCC））评估了一线伊匹单抗和纳武单抗治疗的转移性肾细胞癌（mRCC）的血清CRP水平的预测价值。接受伊匹单抗和纳武单抗治疗IMCD（国际转移性RCC数据库联盟）定义的中度或低风险RCC的74例患者的治疗记录。所有74例mRCC患者的1年总生存率（OS）和客观缓解率分别为65%和41%。受试者工作特征曲线确定血清CRP水平1.0 mg/dL为预测总生存期（OS）的理想截止值。在ccRCC（58例患者：p = 0.009）和nccRCC（16例患者：p = 0.008）中，CRP > 1 mg/dL患者的OS显著短于CRP < 1 mg/dL患者。目前的研究表明，血清CRP水平是OS的预后指标。血清C反应蛋白（CRP）是全身炎症反应的生物标志物。在本研究中，我们试图使用我们的真实世界临床数据集（包括非透明细胞RCC（nccRCC））测量一线伊匹单抗和纳武单抗治疗的转移性肾细胞癌（mRCC）的血清CRP水平的预测价值。回顾性分析了2018年至2021年接受一线ipilimumab联合nivolumab治疗mRCC（包括ccRCC和nccRCC）的患者的临床记录。所有患者均被诊断为IMCD（国际转移性RCC数据库联盟）定义的中危组或低危组。共涉及74例患者。中位年龄为68岁，24例（32.4%）患者在随访期间死亡。45例（61%）和29例（39%）患者分为中度和低度风险组。所有74例mRCC患者的1年总生存率（OS）和客观缓解率分别为65%和41%。受试者工作特征曲线确定血清CRP水平1.0 mg/dL为预测总生存期（OS）的理想截止值。在74例mRCC患者中，血清CRP > 1.0 mg/dL和nccRCC是OS的独立预测因子。在ccRCC（58例患者：p = 0.009）和nccRCC（16例患者：p = 0.008）中，CRP > 1 mg/dL患者的OS显著短于CRP < 1 mg/dL患者。本研究表明，血清CRP水平是一线伊匹单抗加纳武单抗治疗的ccRCC和nccRCC患者的OS预后指标。
Elevated serum C-reactive protein (CRP) level is one of the most established markers of systemic inflammation, potentially affecting tumor immune-microenvironmental status. Thus, we assessed the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear cell RCC (nccRCC). Treatment record of 74 patients treated with ipilimumab and nivolumab for intermediate or poor-risk RCC defined by IMCD (international metastatic RCC database consortium). The one-year overall survival (OS) rate and objective response rate were 65% and 41% for all 74 mRCC patients, respectively. The receiver operating characteristic curve identified 1.0 mg/dL of serum CRP level as an ideal cut-off for predicting overall survival (OS). OS for patients with CRP > 1 mg/dL was significantly shorter than those with CRP < 1 mg/dL in both ccRCC (58 patient: p = 0.009) and nccRCC (16 patients: p = 0.008). The present study suggested that serum CRP level is a prognostic indicator for OS. Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought to measure the predictive value of serum CRP level for metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear cell RCC (nccRCC). The clinical record of patients who underwent the first-line ipilimumab plus nivolumab treatment for mRCC including ccRCC and nccRCC from 2018 to 2021 was retrospectively analyzed. All patients were diagnosed with either intermediate or poor-risk group defined by IMCD (international metastatic RCC database consortium). In total, 74 patients were involved. The median age was 68 years and 24 (32.4%) patients deceased during the follow-up. Forty-five (61%) and 29 (39%) patients were classified into intermediate and poor-risk groups. The one-year overall survival (OS) rate and objective response rate were 65% and 41% for all 74 mRCC patients, respectively. The receiver operating characteristic curve identified 1.0 mg/dL of serum CRP level as an ideal cut-off for predicting overall survival (OS). Serum CRP > 1.0 mg/dL and nccRCC were the independent predictors for OS in 74 mRCC patients. OS for patients with CRP > 1 mg/dL was significantly shorter than those with CRP < 1 mg/dL in both ccRCC (58 patient: p = 0.009) and nccRCC (16 patients: p = 0.008). The present study indicated that serum CRP level is a prognostic indicator for OS in both ccRCC and nccRCC patients treated with the first-line ipilimumab plus nivolumab treatment.
登录
查看更多内容
DOI：
10.1016/j.urolonc.2019.04.002
发表时间：
2019-11-01
影响因子：
2.7
作者：
Tsujino, Takuya;Komura, Kazumasa;Azuma, Haruhito
通讯作者：
Azuma, Haruhito
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
--
作者：
Tsujino T;Komura K;Ichihashi A;Tsutsumi T;Matsunaga T;Yoshikawa Y;Maenosono R;Okita K;Takai T;Oide R;Minami K;Uehara H;Taniguchi K;Hirano H;Nomi H;Ibuki N;Takahara K;Inamoto T;Azuma H
通讯作者：
Azuma H
影响因子：
7.3
作者：
Tomita, Y.;Larkin, J.;Venugopal, B.;Haanen, J.;Kanayama, H.;Eto, M.;Grimm, M-O;Fujii, Y.;Umeyama, Y.;Huang, B.;Mariani, M.;di Pietro, A.;Choueiri, T. K.
通讯作者：
Choueiri, T. K.
影响因子：
158.5
作者：
Motzer, Robert;Alekseev, Boris;Choueiri, Toni K.
通讯作者：
Choueiri, Toni K.